In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Jennifer Schranz, head of rare diseases at Ipsen, for a conversation focused on rare liver disease primary biliary cholangitis (PBC ...

In Part 5 of our Life Sciences Industry Report, we turn our attention to the oncological field of research and development, from cancer therapies to cancer care, from clinical trials to the patient’s ...

Take a look at three predictions for the year ahead for pharma executives considering AI implementation and adoption. For AI to live up to its potential, pharma executives need to not simply invest in ...

Spinraza remains a big product for Biogen, but has seen its sales go into reverse as competition in SMA treatment has emerged ...

BV100 is a new formulation of rifabutin suitable for intravenous administration that BioVersys claims offers a new mechanism ...

President Trump's pick to lead the Department of Health and Human Services (HHS), Robert F Kennedy Jr, will be scrutinised at ...

The innovation showcased at CES highlights how practical solutions can meet niche, but impactful, health challenges. These ...

The ranges were 4.5 to nine years for men and 6.5 to 11 years for women, according to the researchers, who have published ...

The new data comes from the phase 3 ALLEVIATE-1 trial, which compared cebranopadol to placebo for the management of ...

Babylon Health's efforts to raise financing to steady its business have been scuppered by the collapse of a proposed merger with digital therapeutics firm MindMaze, which would have taken it back ...

Thousands of UK patients with advanced kidney cancer who have been denied a combination regimen based on Ipsen’s Cabometyx and Bristol-Myers Squibb’s Opdivo will now be able to access the ...

As the race to deliver personalised engagement at scale heats up, artificial intelligence (AI) has become the critical differentiator for pharma companies, turning vast data streams into ...